Daily therapy with a non-vitamin K antagonist oral anticoagulant (NOAC) can dramatically lower the incidence of venous thromboembolism (VTE) in patients with cancer who are at moderate-to-high risk for developing a clot, according to the results of two new studies.
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide-a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)-plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating…
Iovance stock sank after phase 2 Amtagvi lung cancer data. Read more here. Rasi Bhadramani/iStock via Getty Images - Iovance Biotherapeutics (IOVA) is down ~34% in Thursday trading after releasing data for two cohorts of a phase 2 trial of Amtagvi (lifileucel) for…
Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer October 29, 2026 8:30 AM EDT Sara Pellegrino - Senior Vice President of Investor Relations & Corporate CommunicationsFrederick Vogt - Interim CEO, President, General Counsel, Corporate Secretary & Director Lin…
2026-10-29. The following slide deck was published by Iovance Biotherapeutics, Inc. in conjunction with this event.
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments At an Oct. 14, 2026, data cutoff, 17 of 69 patients in Cohorts 1 and 2 had responded to treatment, representing an objective response rate of about 25% under RECIST 1.1 criteria, according to Interim Chief Executive…
Randomized, placebo-controlled study to evaluate the safety, tolerability, and efficacy in a robust, two-part study First-in-class therapeutic targets Alveolar Epithelial Type 2 (AEC2) cells with the aim to halt disease progression and promote repair of fibrotic damage in IPF The ORBIT-IPF is…
CIMAvax effectively starves cancer cells by stimulating an immune response against circulating EGF, which the cells need to grow and proliferate. The now-completed phase I clinical study led by Dr. Dy evaluated the safety of combining CIMAvax with nivolumab, an…
KRAS is the most frequently mutated oncogene across all human cancers. Although different KRAS mutations have long been thought to exert the same cancer-driving effects, a new study led by UT Southwestern Medical Center researchers suggests that different KRAS mutation…
With an expected 333,830 new cases in 2026, prostate cancer remains the most common malignancy in men in the United States. Further, experts predict that prostate cancer will account for about 11% of all cancer-related deaths this year. One intervention which has shown…
New cancer treatments across types: trial results, targeted drugs, chemotherapy, radiotherapy and surgery advances, and cancer drug approvals.
An article joins this feed when it matches these terms. Each one is also a search of its own.